Table 1.
Clinicopathological characteristics and tumor expression of KIF20A in patients with early-stage cervical squamous cell carcinoma.
Fig 1.
Upregulation of KIF20A mRNA and protein in cervical cancer cell lines.
A, B Expression of KIF20A mRNA and protein in cervical cancer cell lines (HeLa, ME-180, HeLa229, SiHa, CasKi, HCC94, MS751, C33A) and normal cervical cell lines were examined by Western blotting (A) and qPCR (B). Expression levels were normalized against α-Tubulin and GAPDH respectively. Error bars represent the standard deviation of the mean (SD) calculated from three parallel experiments. *P < 0.05.
Fig 2.
Aberrant expression of KIF20A mRNA and protein in early-stage cervical squamous cell carcinoma tissues.
(A) Representative images of western blotting analyses of KIF20A protein expression in eight matched pairs of cervical cancer tissue samples (T) and adjacent noncancerous tissues (ANT). α-Tubulin was used as the loading control. (B) The average T/ANT ratios of KIF20A mRNA expression in the paired cervical cancer (T) and adjacent noncancerous tissue sections (ANT) were quantified using qPCR and normalised against GAPDH. The error bars represent the standard deviation of the mean (SD), which was calculated from three parallel experiments. (C) Immunohistochemical staining of KIF20A protein in eight pairs of matched early-stage cervical squamous cell carcinoma tissues. *P < 0.05.
Fig 3.
Expression of the KIF20A protein in archived paraffin-embedded early-stage cervical squamous cell carcinoma tissue sections by immunohistochemistry.
A. Representative images from immunohistochemistry analyses of KIF20A expression in normal cervical epithelium tissue and different FIGO stages of early-stage cervical squamous cell carcinoma tissues. B. Patients with higher KIF20A expression in tumor were closely correlated with poorer overall survival (left) and recurrence-free survival (right) than that with tumor with lower KIF20A expression (P < 0.05, respectively).
Table 2.
Correlation between KIF20A protein expression and the clinicopathologic features of patients with early-stage cervical squamous cell carcinoma.
Table 3.
Correlation between KIF20A protein expression and the clinicopathological characteristics of patients with early-stage cervical squamous cell carcinoma.
Fig 4.
Kaplan-Meier curves of univariate analysis data (log-rank test) in select patient subgroups.
Survival curves for the patients (A) with age > 46 years, (B) with age ≤ 46 years, (C) at stages IB1-IB2, (D) at stages IIA1-IIA2, (E) with tumor size ≥ 4cm, (F) with tumor size < 4cm, (G) with SCC > 1.5ng/ml, (G) with HPV infection, (H) with lymph node metastasis, (I) without lymph node metastasis, (J) at differentiation grade 1,2, (K) at differentiation grade 2,3.(P < 0.05, respectively).
Fig 5.
Survival curves for the patients in select patient subgroups (log-rank test).
OS rates for patients (A) with myometrium ≥ 1/2, (B) with myometrium<1/2, (C) without property of surgical margin, (D) without infiltration of parauterine organ, (E) without lymphovascular space involvement, (F) with chemotherapy, (G) without chemotherapy, (H) without radiation, (I) without concurrent chemoradiation.(P < 0.05, respectively).
Table 4.
Univariate and multivariate analyses of prognostic factors in early-stage cervical squamous cell carcinoma using a Cox-regression model.